RESUMEN
Small-molecule modulators of TLR8 have drawn much interests as it plays pivotal roles in the innate immune response to single-stranded RNAs (ssRNAs) derived from viruses. However, their clinical uses are limited because they can invoke an uncontrolled, global inflammatory response. The efforts described herein culminate in the fortuitous discovery of a tetrasubstituted imidazole CU-CPD107 which inhibits R848-induced TLR8 signaling. In stark contrast, CU-CPD107 shows unexpected synergistic agonist activities in the presence of ssRNA, while CU-CPD107 alone is unable to influence TLR8 signaling. CU-CPD107's unique, dichotomous behavior sheds light on a way to approach TLR agonists. CU-CPD107 offers the opportunity to avoid the undesired, global inflammation side effects that have rendered imidazoquinolines clinically irrelevant, providing an insight for the development of antiviral drugs.
Asunto(s)
Imidazoles/farmacología , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 8/agonistas , Receptor Toll-Like 8/antagonistas & inhibidores , Calorimetría , Células HEK293 , Humanos , Imidazoles/síntesis química , Imidazoles/química , Inflamación , Simulación del Acoplamiento Molecular , Quinolinas/química , Quinolinas/farmacología , ARN/química , ARN/farmacología , Proteínas Recombinantes , Transducción de Señal/inmunología , Relación Estructura-Actividad , Receptor Toll-Like 8/química , Receptor Toll-Like 8/metabolismo , Difracción de Rayos XRESUMEN
Rational designs of small-molecule inhibitors targeting protein-protein interfaces have met little success. Herein, we have designed a series of triazole derivatives with a novel scaffold to specifically intervene with the interaction of TLR8 homomerization. In multiple assays, TH1027 was identified as a highly potent and specific inhibitor of TLR8. A successful solution of the X-ray crystal structure of TLR8 in complex with TH1027 provided an in-depth mechanistic insight into its binding mode, validating that TH1027 was located between two TLR8 monomers and recognized as an unconventional pocket, thereby preventing TLR8 from activation. Further biological evaluations showed that TH1027 dose-dependently suppressed the TLR8-mediated inflammatory responses in both human monocyte cell lines, peripheral blood mononuclear cells, and rheumatoid arthritis patient specimens, suggesting a strong therapeutic potential against autoimmune diseases.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Diseño de Fármacos , Dominios y Motivos de Interacción de Proteínas/fisiología , Receptor Toll-Like 8/antagonistas & inhibidores , Receptor Toll-Like 8/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Dominios y Motivos de Interacción de Proteínas/efectos de los fármacos , Estructura Secundaria de Proteína , Relación Estructura-ActividadRESUMEN
Rational design of drug-like small-molecule ligands based on structural information of proteins remains a significant challenge in chemical biology. In particular, designs targeting protein-protein interfaces have met little success given the dynamic nature of the protein surfaces. Herein, we utilized the structure of a small-molecule ligand in complex with Toll-like receptor 8 (TLR8) as a model system due to TLR8's clinical relevance. Overactivation of TLR8 has been suggested to play a prominent role in the pathogenesis of various autoimmune diseases; however, there are still few small-molecule antagonists available, and our rational designs led to the discovery of six exceptionally potent compounds with â¼picomolar IC50 values. Two X-ray crystallographic structures validated the contacts within the binding pocket. A variety of biological evaluations in cultured cell lines, human peripheral blood mononuclear cells, and splenocytes from human TLR8-transgenic mice further demonstrated these TLR8 inhibitors' high efficacy, suggesting strong therapeutic potential against autoimmune disorders.
Asunto(s)
Bibliotecas de Moléculas Pequeñas/química , Bibliotecas de Moléculas Pequeñas/farmacología , Receptor Toll-Like 8/antagonistas & inhibidores , Animales , Enfermedades Autoinmunes/tratamiento farmacológico , Sitios de Unión , Células Cultivadas , Diseño Asistido por Computadora , Cristalografía por Rayos X , Diseño de Fármacos , Células HEK293 , Humanos , Ratones , Simulación del Acoplamiento Molecular , Receptor Toll-Like 8/química , Receptor Toll-Like 8/metabolismoRESUMEN
Endosomal Toll-like receptors (TLR3, TLR7, TLR8, and TLR9) are highly analogous sensors for various viral or bacterial RNA and DNA molecular patterns. Nonetheless, few small molecules can selectively modulate these TLRs. In this manuscript, we identified the first human TLR8-specific small-molecule antagonists via a novel inhibition mechanism. Crystal structures of two distinct TLR8-ligand complexes validated a unique binding site on the protein-protein interface of the TLR8 homodimer. Upon binding to this new site, the small-molecule ligands stabilize the preformed TLR8 dimer in its resting state, preventing activation. As a proof of concept of their therapeutic potential, we have demonstrated that these drug-like inhibitors are able to suppress TLR8-mediated proinflammatory signaling in various cell lines, human primary cells, and patient specimens. These results not only suggest a novel strategy for TLR inhibitor design, but also shed critical mechanistic insight into these clinically important immune receptors.
Asunto(s)
Bibliotecas de Moléculas Pequeñas/farmacología , Receptor Toll-Like 8/antagonistas & inhibidores , Artritis Reumatoide/inmunología , Sitios de Unión , Línea Celular , Proliferación Celular/efectos de los fármacos , Humanos , Inmunidad Innata , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Ligandos , Modelos Moleculares , Multimerización de Proteína , Estabilidad Proteica , Bibliotecas de Moléculas Pequeñas/química , Membrana Sinovial/efectos de los fármacos , Membrana Sinovial/inmunología , Receptor Toll-Like 8/genética , Receptor Toll-Like 8/inmunología , TransfecciónRESUMEN
Toll-like receptor 7 (TLR7) is a single-stranded RNA (ssRNA) sensor in innate immunity and also responds to guanosine and chemical ligands, such as imidazoquinoline compounds. However, TLR7 activation mechanism by these ligands remain largely unknown. Here, we generated crystal structures of three TLR7 complexes, and found that all formed an activated m-shaped dimer with two ligand-binding sites. The first site conserved in TLR7 and TLR8 was used for small ligand-binding essential for its activation. The second site spatially distinct from that of TLR8 was used for a ssRNA-binding that enhanced the affinity of the first-site ligands. The first site preferentially recognized guanosine and the second site specifically bound to uridine moieties in ssRNA. Our structural, biochemical, and mutagenesis studies indicated that TLR7 is a dual receptor for guanosine and uridine-containing ssRNA. Our findings have important implications for understanding of TLR7 function, as well as for therapeutic manipulation of TLR7 activation.
Asunto(s)
Guanosina/metabolismo , ARN/metabolismo , Receptor Toll-Like 7/química , Receptor Toll-Like 7/metabolismo , Animales , Sitios de Unión/inmunología , Línea Celular , Drosophila , Guanosina/inmunología , Células HEK293 , Humanos , Inmunidad Innata/inmunología , Ligandos , Macaca mulatta , ARN/inmunología , Receptor Toll-Like 7/inmunologíaRESUMEN
Toll-like receptor 8 (TLR8) senses single-stranded RNA (ssRNA) and initiates innate immune responses. TLR8 requires proteolytic cleavage at the loop region (Z-loop) between leucine-rich repeat (LRR) 14 and LRR15 for its activation. However, the molecular basis of Z-loop processing remains unknown. To elucidate the mechanism of Z-loop processing, we performed biochemical and structural studies of how the Z-loop affects the function of TLR8. TLR8 with the uncleaved Z-loop is unable to form a dimer, which is essential for activation, irrespective of the presence of agonistic ligands. Crystallographic analysis revealed that the uncleaved Z-loop located on the ascending lateral face prevents the approach of the dimerization partner by steric hindrance. This autoinhibition mechanism of dimerization by the Z-loop might be occurring in the proteins of the same subfamily, TLR7 and TLR9.
Asunto(s)
Procesamiento Proteico-Postraduccional , Receptor Toll-Like 8/metabolismo , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Cristalografía por Rayos X , Dimerización , Genes Reporteros , Células HEK293 , Humanos , Ligandos , Modelos Moleculares , Datos de Secuencia Molecular , FN-kappa B/metabolismo , Péptido Hidrolasas/metabolismo , Unión Proteica , Conformación Proteica , Estructura Terciaria de Proteína , Proteolisis , Proteínas Recombinantes de Fusión/metabolismo , Alineación de Secuencia , Receptor Toll-Like 8/química , Receptor Toll-Like 8/genéticaRESUMEN
Activation of human toll-like receptor-8 (TLR8), expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells, evokes a distinct cytokine profile which favors the development of Type 1 helper T cells. Part-structures of the 2-aminobenzimidazole scaffold were examined with a view to identifying structural requisites corresponding to the smallest possible fragment of the benzimidazole core that would allow for retention of TLR8-agonistic activity. TLR8-specific agonistic activity was retained in 1-pentyl-4-phenyl-1H-imidazol-2-amine. The crystal structure of this compound bound to the TLR8 ectodomain displayed binding interactions that are common to other TLR8 agonists. This compound showed markedly attenuated proinflammatory properties in ex vivo human blood models. SAR studies revealed that 4-(2-(benzyloxy)phenyl)-1-pentyl-1H-imidazol-2-amine inhibited TLR signaling in a variety of TLR reporter cell lines, as well as in pharmacologically relevant human blood model systems. A kinase screen of this compound showed relative specificity for calmodulin kinases.
Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/antagonistas & inhibidores , Citocinas/metabolismo , Imidazoles/química , Imidazoles/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Receptor Toll-Like 8/agonistas , Células Cultivadas , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Monocitos/citología , Monocitos/efectos de los fármacos , Monocitos/metabolismo , FN-kappa B/metabolismo , Inhibidores de Proteínas Quinasas/química , Transducción de Señal/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
Human Toll-like receptor 8 (hTLR8) is expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells. Engagement by TLR8 agonists evokes a distinct cytokine profile which favors the development of type 1 helper T cells. Crystal structures of the ectodomain of hTLR8 cocrystallized with two regioisomers of a dual TLR7/8-agonistic N1-substituted imidazoquinolines showed subtle differences in their interactions in the binding site of hTLR8. We hypothesized that the potency of a previously reported best-in-class pure TLR8 agonist, 3-pentylquinoline-2-amine, could be further enhanced by "designing in" functional groups that would mimic key intermolecular interactions that we had observed in the crystal structures. We performed a focused exploration of decorating the quinoline core with alkylamino groups at all possible positions. These studies have led to the identification of a novel TLR8 agonist that was â¼ 20-fold more potent than the parent compound and displays prominent adjuvantic activity in a rabbit model of immunization.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Relación Estructura-Actividad , Receptor Toll-Like 8/agonistas , Inmunidad Adaptativa/efectos de los fármacos , Adyuvantes Inmunológicos/química , Animales , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos/métodos , Femenino , Humanos , Conformación Proteica , Quinolinas/química , Conejos , Receptor Toll-Like 8/química , Receptor Toll-Like 8/genéticaRESUMEN
BACKGROUND: Newborns and young infants are at higher risk for infections than adults, and manifest suboptimal vaccine responses, motivating a search for novel immunomodulators and/or vaccine adjuvants effective in early life. In contrast to most TLR agonists (TLRA), TLR8 agonists such as imidazoquinolines (IMQs) induce adult-level Th1-polarizing cytokine production from human neonatal cord blood monocytes and are candidate early life adjuvants. We assessed whether TLR8-activating IMQ congeners may differ in potency and efficacy in inducing neonatal cytokine production in vitro, comparing the novel TLR7/8-activating IMQ analogues Hybrid-2, Meta-amine, and Para-amine to the benchmark IMQ resiquimod (R848). METHODS: TLRA-induced NF-κB activation was measured in TLR-transfected HEK cells. Cytokine production in human newborn cord and adult peripheral blood and in monocyte-derived dendritic cell cultures were measured by ELISA and multiplex assays. X-ray crystallography characterized the interaction of human TLR8 with Hybrid-2. RESULTS: Hybrid-2 selectively activated both TLR7 and 8 and was more potent than R848 in inducing adult-like levels of TNF-α, and IL-1ß. Consistent with its relatively high in vitro activity, crystallographic studies suggest that absence in Hybrid-2 of an ether oxygen of the C2-ethoxymethyl substituent, which can engage in unfavorable electrostatic and/or dipolar interactions with the carbonyl oxygen of Gly572 in human TLR8, may confer greater efficacy and potency compared to R848. CONCLUSIONS: Hybrid-2 is a selective and potent TLR7/8 agonist that is a candidate adjuvant for early life immunization.
Asunto(s)
Citocinas/metabolismo , Imidazoles/farmacología , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Quinolinas/farmacología , Proteínas Recombinantes de Fusión/farmacología , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 8/agonistas , Adulto , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Femenino , Sangre Fetal/citología , Sangre Fetal/efectos de los fármacos , Sangre Fetal/metabolismo , Células HEK293 , Humanos , Inmunosupresores/farmacología , Recién Nacido , Embarazo , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Innate immunity serves as the first line of defence against invading pathogens such as bacteria and viruses. Toll-like receptors (TLRs) are examples of innate immune receptors, which sense specific molecular patterns from pathogens and activate immune responses. TLR9 recognizes bacterial and viral DNA containing the cytosine-phosphate-guanine (CpG) dideoxynucleotide motif. The molecular basis by which CpG-containing DNA (CpG-DNA) elicits immunostimulatory activity via TLR9 remains to be elucidated. Here we show the crystal structures of three forms of TLR9: unliganded, bound to agonistic CpG-DNA, and bound to inhibitory DNA (iDNA). Agonistic-CpG-DNA-bound TLR9 formed a symmetric TLR9-CpG-DNA complex with 2:2 stoichiometry, whereas iDNA-bound TLR9 was a monomer. CpG-DNA was recognized by both protomers in the dimer, in particular by the amino-terminal fragment (LRRNT-LRR10) from one protomer and the carboxy-terminal fragment (LRR20-LRR22) from the other. The iDNA, which formed a stem-loop structure suitable for binding by intramolecular base pairing, bound to the concave surface from LRR2-LRR10. This structure serves as an important basis for improving our understanding of the functional mechanisms of TLR9.
Asunto(s)
Islas de CpG/inmunología , ADN/química , ADN/inmunología , Receptor Toll-Like 9/química , Receptor Toll-Like 9/inmunología , Animales , Secuencia de Bases , Cristalografía por Rayos X , ADN/genética , ADN/metabolismo , Humanos , Ligandos , Modelos Moleculares , Conformación de Ácido Nucleico , Estructura Terciaria de Proteína , Relación Estructura-Actividad , Receptor Toll-Like 9/agonistas , Receptor Toll-Like 9/antagonistas & inhibidoresRESUMEN
Toll-like receptor 8 (TLR8) recognizes viral or bacterial single-stranded RNA (ssRNA) and activates innate immune systems. TLR8 is activated by uridine- and guanosine-rich ssRNA as well as by certain synthetic chemicals; however, the molecular basis for ssRNA recognition has remained unknown. In this study, to elucidate the recognition mechanism of ssRNA, we determined the crystal structures of human TLR8 in complex with ssRNA. TLR8 recognized two degradation products of ssRNAuridine and a short oligonucleotideat two distinct sites: uridine bound the site on the dimerization interface where small chemical ligands are recognized, whereas short oligonucleotides bound a newly identified site on the concave surface of the TLR8 horseshoe structure. Site-directed mutagenesis revealed that both binding sites were essential for activation of TLR8 by ssRNA. These results demonstrate that TLR8 is a sensor for both uridine and a short oligonucleotide derived from RNA.
Asunto(s)
ARN/química , ARN/metabolismo , Receptor Toll-Like 8/química , Receptor Toll-Like 8/metabolismo , Animales , Sitios de Unión , Calorimetría , Línea Celular , Cromatografía Liquida , Cristalografía por Rayos X , Drosophila , Humanos , Espectrometría de Masas , Mutagénesis Sitio-Dirigida , Estructura Terciaria de Proteína , Receptor Toll-Like 8/genéticaRESUMEN
Toll-like receptor (TLR) 7 and 8 agonists are potential vaccine adjuvants, since they directly activate APCs and enhance Th1-driven immune responses. Previous SAR investigations in several scaffolds of small molecule TLR7/8 activators pointed to the strict dependence of the selectivity for TLR7 vis-à-vis TLR8 on the electronic configurations of the heterocyclic systems, which we sought to examine quantitatively with the goal of developing "heuristics" to define structural requisites governing activity at TLR7 and/or TLR8. We undertook a scaffold-hopping approach, entailing the syntheses and biological evaluations of 13 different chemotypes. Crystal structures of TLR8 in complex with the two most active compounds confirmed important binding interactions playing a key role in ligand occupancy and biological activity. Density functional theory based quantum chemical calculations on these compounds followed by linear discriminant analyses permitted the classification of inactive, TLR8-active, and TLR7/8 dual-active compounds, confirming the critical role of partial charges in determining biological activity.
Asunto(s)
Compuestos Heterocíclicos/química , Relación Estructura-Actividad Cuantitativa , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 8/agonistas , Quimiocinas/biosíntesis , Citocinas/biosíntesis , Compuestos Heterocíclicos/farmacología , Humanos , Receptor Toll-Like 7/química , Receptor Toll-Like 7/fisiología , Receptor Toll-Like 8/química , Receptor Toll-Like 8/fisiologíaRESUMEN
Toll-like receptors (TLRs) sense pathogen-associated molecular patterns originating from invading microorganisms and initiate innate immune responses. Recent structural studies of TLR-ligand complexes have revealed the detailed molecular mechanisms by which each TLR specifically recognizes its own ligands. This review focuses on the structure of TLR8 and discusses the similarities and diversities of TLR-ligand interactions and signaling mechanisms.
Asunto(s)
Receptores Inmunológicos/química , Receptores Inmunológicos/metabolismo , Receptor Toll-Like 8/química , Receptor Toll-Like 8/metabolismo , Humanos , Modelos Moleculares , Unión Proteica , Transducción de SeñalRESUMEN
Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds might be promising candidate vaccine adjuvants. Recently, a C2-butyl furo[2,3-c]quinoline was reported with purely TLR8 agonistic activity. This compound was successfully co-crystallized with the human TLR8 ectodomain, and the co-crystal structure revealed ligand-induced reorganization of the binding pocket of TLR8. The loss of a key hydrogen bond between the oxygen atom of the furanyl ring of the agonist and Thr 574 in TLR8 suggested that the furan ring is dispensable. Employing a disconnection strategy, 3- and 4-substituted aminoquinolines were investigated. Focused structure-based ligand design studies led to the identification of 3-pentyl-quinoline-2-amine as a novel, structurally simple, and highly potent human TLR8-specific agonist (EC50 =0.2 µM). Preliminary evaluation of this compound in ex vivo human blood assay systems revealed that it retains prominent cytokine-inducing activity. Together, these results indicate the suitability of this compound as a novel vaccine adjuvant, warranting further investigation.
Asunto(s)
Aminoquinolinas/farmacología , Diseño de Fármacos , Receptor Toll-Like 8/agonistas , Aminoquinolinas/síntesis química , Aminoquinolinas/química , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Toll-like receptor 7 (TLR7) and TLR8 recognize single-stranded RNA and initiate innate immune responses. Several synthetic agonists of TLR7-TLR8 display novel therapeutic potential; however, the molecular basis for ligand recognition and activation of signaling by TLR7 or TLR8 is largely unknown. In this study, the crystal structures of unliganded and ligand-induced activated human TLR8 dimers were elucidated. Ligand recognition was mediated by a dimerization interface formed by two protomers. Upon ligand stimulation, the TLR8 dimer was reorganized such that the two C termini were brought into proximity. The loop between leucine-rich repeat 14 (LRR14) and LRR15 was cleaved; however, the N- and C-terminal halves remained associated and contributed to ligand recognition and dimerization. Thus, ligand binding induces reorganization of the TLR8 dimer, which enables downstream signaling processes.